文献速递肿瘤 PET/CT核素与放射性配体治疗

64CuCl2在人前列腺癌中的生物动力学与剂量学特征:可能的诊疗一体化意义

Biokinetic and dosimetric aspects of 64CuCl2 in human prostate cancer: possible theranostic implications.
PubMed 文献 · EJNMMI Res · 2018-03-01

该前瞻性研究纳入50例术后或外照射放疗后生化复发的前列腺癌患者,行64CuCl2-PET/CT检测复发/转移灶,计算动力学参数与吸收剂量。淋巴结平均有效半衰期10.2±1.7 h,显著高于局部复发8.8±1.1 h,与骨转移9.0±0.4 h相似;注射后1 h淋巴结与骨转移SUVmax均显著高于局部复发。按给药活度计算的病灶平均吸收剂量为6.00E-2±4.74E-2 mGy/MBq,给予3.7 GBq时病灶平均吸收剂量约为0.22 Gy。

要点

  • 64CuCl2在淋巴结的平均有效半衰期为10.2±1.7 h,显著高于局部复发的8.8±1.1 h
  • 注射后1 h淋巴结与骨转移SUVmax均为6.8,显著高于局部复发的4.7±2.4
  • 病灶平均吸收剂量为6.00E-2±4.74E-2 mGy/MBq,给予3.7 GBq时约为0.22 Gy

核心结论

  • 剂量学显示前列腺癌复发/转移灶按给药活度计算的吸收剂量较低。
  • 所进行的剂量学研究未考虑俄歇电子的可能治疗效应。
  • 需要临床试验评估64Cu进入细胞核的情况,其似乎与临床前研究报道的治疗有效性相关。

研究设计与样本

  • 前瞻性评估50例术后或外照射放疗后生化复发的前列腺癌患者。
  • 所有患者行64CuCl2-PET/CT以检测前列腺癌复发/转移。
  • 对每例患者mpMRI上直径>1 cm的每个64CuCl2高摄取前列腺癌病灶手动勾画感兴趣区。
  • 获得所有病灶的时间-放射性曲线,计算有效与生物学半衰期及标准摄取值(SUV)。
  • 考虑肿瘤/本底比(TBR)随时间变化的曲线,并估算每个病灶的吸收剂量。

主要发现

  • 淋巴结中64CuCl2平均有效半衰期为10.2±1.7 h,显著高于局部复发的8.8±1.1 h,与骨转移的9.0±0.4 h相似。
  • 注射示踪剂后1 h淋巴结平均SUVmax为6.8±4.3、骨转移为6.8±2.9,均显著高于局部复发的4.7±2.4。
  • 64CuCl2的TBR平均曲线显示,局部复发、淋巴结转移和骨转移的TBRmax分别为5.0、7.0和6.2,约在注射后1 h达到。
  • 前列腺癌病灶按给药活度计算的平均吸收剂量为6.00E-2±4.74E-2 mGy/MBq。
  • 给予3.7 GBq活度时,病灶平均吸收剂量约为0.22 Gy。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 所进行的剂量学研究未考虑俄歇电子的可能治疗效应。
  • 需要临床试验评估64Cu进入细胞核的情况,其似乎与临床前研究报道的治疗有效性相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aim of the present study is to evaluate the kinetics and dosimetry of 64CuCl2 in human prostate cancer (PCa) lesions. We prospectively evaluated 50 PCa patients with biochemical relapse after surgery or external beam radiation therapy. All patients underwent 64CuCl2-PET/CT to detect PCa recurrence/metastases. Volumes of interest were manually drawn for each 64CuCl2 avid PCa lesion with a diameter > 1 cm on mpMRI in each patient. Time-activity curves for all lesions were obtained. The effective and biological half-life and the standard uptake values (SUVs) were calculated. Tumour/background ratio (TBR) curves as a function of time were considered. Finally, the absorbed dose per lesion was estimated. RESULTS: The mean effective half-life of 64CuCl2 calculated in the lymph nodes (10.2 ± 1.7 h) was significantly higher than in local relapses (8.8 ± 1.1 h) and similar to that seen in bone metastases (9.0 ± 0.4 h). The mean 64CuCl2 SUVmax calculated 1 h after tracer injection was significantly higher in the lymph nodes (6.8 ± 4.3) and bone metastases (6.8 ± 2.9) than in local relapses (4.7 ± 2.4). TBR mean curve of 64CuCl2 revealed that the calculated TBRmax value was 5.0, 7.0, and 6.2 in local relapse and lymph node and bone metastases, respectively, and it was achieved about 1 h after 64CuCl2 injection. The mean absorbed dose of the PCa lesions per administrated activity was 6.00E-2 ± 4.74E-2mGy/MBq. Indeed, for an administered activity of 3.7 GBq, the mean dose absorbed by the lesion would be 0.22 Gy. CONCLUSIONS: Dosimetry showed that the dose absorbed by PCa recurrences/metastases per administrated activity was low. The dosimetric study performed does not take into account the possible therapeutic effect of the Auger electrons. Clinical trials are needed to evaluate 64Cu internalization in the cell nucleus that seems related to the therapeutic effectiveness reported in preclinical studies.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Righi S, Ugolini M, Bottoni G, et al. Biokinetic and dosimetric aspects of 64CuCl2 in human prostate cancer: possible theranostic implications. EJNMMI Res. 2018. PMID: 29492782. doi:10.1186/s13550-018-0373-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。